Patient Identification
Patient Identification
LYFNUA®▼ (gefapixant)
Prescribing Information [External link]
LYFNUA is indicated in adults for the treatment of refractory and unexplained chronic cough1
LYFNUA is available by private prescription only and is not available via the NHS
It is estimated that 6.2% of UK adults will experience chronic cough during their lifetime2
- Chronic cough is more prevalent in women than men and in respondents ≥50 years old2
- Sufferers experience significantly impaired quality of life (QoL)3
Common underlying conditions of chronic cough include asthma, gastroesophageal reflux disease (GERD), upper airway cough syndrome (UACS), and nonasthmatic eosinophilic bronchitis (NAEB).4,5
Common characteristics of chronic cough
Patients with chronic cough may share a common clinical presentation.5
- Dry or minimally productive cough6
- Uncontrollable bouts of coughing7
- Recurring sensations such as a tickle in the throat or an urge to cough5
- Cough triggered by nontussive stimuli which do not normally cause cough (cold air, perfume, voice projection, or exercise)8
- Cough triggered by smaller amounts of known cough inducing stimuli (strong smells from fumes, bleach, aerosols, or second-hand smoke)7,9
There has been major progress in the diagnosis, and therapy of chronic cough, however it is often a frequently misunderstood disease.10-12
Introducing LYFNUA®▼ (gefapixant)
A treatment that significantly reduces 24-hour cough frequency in patients with refractory or unexplained chronic cough (RCC)1
- Clinical guidelines define a subset of chronic cough (>8 weeks) as refractory or unexplained chronic cough4,5
- Refractory or unexplained chronic cough (RCC): persistent cough despite thorough investigation and/or treatment according to published practice guidelines4,5
Always refer to the full Summary of Product Characteristics before prescribing for up to-date and complete safety considerations to help minimise the risks associated with the use of LYFNUA.
Please click here for the Summary of Product Characteristics [External link]
Stay informed about the latest on LYFNUA
Click the sign up button and consent to receive promotional emails, resources and invitations to meetings
References
- LYFNUA Summary of Product Characteristics.
- McGarvey L et al. ERJ Open Res. 2023 Jul 17;9(4):00157-2023.
- Puente-Maestu L et al. ERJ Open Res. 2023 Sep 25;9(5):00425-2023.
- Irwin RS et al. Chest. 2018;153:196-209.
- Morice AH et al. Eur Respir J. 2020;55:1901136.
- Satia I et al. Clin Med (Lond). 2016;16(Suppl 6):S92-S97.
- Mazzone SB et al. Lancet Respir Med. 2018;6:636-646.
- Gibson PG. J Allergy Clin Immunol Pract. 2019;7:1724-1729.
- Vertigan AE, Gibson PG. J Voice. 2010;25:596- 601.
- Parker SM et al. Thorax. 2023;78(suppl 6):3-19.
- Mazzone SB and McGarvey L. Clin Pharmacol Ther. 2021;109:619-36.
- Morice AH et al. Eur Respir Rev. 2021;30:210127.
Supporting documentation
LYFNUA®▼ (gefapixant)
Prescribing Information (Great Britain)
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website
